News | RIVM

Launch of the European project RISK-HUNT3R

The new Horizon 2020 project RISK-HUNT3R: RISK assessment of chemicals integrating HUman centric Next generation Testing strategies promoting the 3Rs was launched on 1 June.

State Secretary Blokhuis: boys will also be vaccinated against HPV virus

The vaccine against the HPV human papillomavirus virus will also become available for boys.

Research: HPV vaccine is safe

RIVM research shows no causal link between the vaccine against cervical cancer (HPV) and long-term fatigue symptoms in girls.

Animal-free innovations in safety assessment of chemicals

How can the process of validation, acceptance and use of animal-free innovative approaches to assess the safety of chemicals be facilitated?

Vaccination rate again drops slightly, HPV vaccination rate drops considerably

The vaccination rate for vaccines included in the National Immunisation Programme has dropped slightly by about 1 percent.

Interspecies website transferred from RIVM to Utrecht University

The Interspecies website which helps researchers to reduce and refine the use of laboratory animals is transferred to the 3Rs database Programme of the 3Rs-Centre Utrecht Life Sciences (ULS) of Utr

RIVM and Olive Foundation open trading to mark the European Cervical Cancer Prevention Week

January 20th, the Olive Foundation and RIVM opened AEX trading day in Amsterdam on the occasion of the 9th European Cervical Cancer Prevention Week.

The National Immunisation Programme in the Netherlands 2013 - 2014

Every year, RIVM provides an overview of surveillance and developments in the National Immunisation Programme (NIP).

Increasing number of girls immunised against HPV

In 2014 the number of girls who were immunised against the human papilloma virus (HPV) rose. This virus can cause cervical cancer later in life.

The National Immunisation Programme in the Netherlands: Developments in 2013

Annually RIVM provides an overview of key events and developments in the National Immunisation Programme (NIP).